Provided by Tiger Fintech (Singapore) Pte. Ltd.

Verve Therapeutics

4.59
+0.08001.77%
Post-market: 4.57-0.0200-0.44%19:59 EDT
Volume:2.59M
Turnover:11.98M
Market Cap:407.57M
PE:-1.96
High:4.84
Open:4.56
Low:4.43
Close:4.51
Loading ...

Why Verve Therapeutics Zoomed 40% Higher This Week

Motley Fool
·
1 hour ago

Verve Therapeutics Shares Jump After Cantor Fitzgerald Upgrade

MT Newswires Live
·
16 Apr

VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study

Zacks
·
16 Apr

Verve Therapeutics Raised to Overweight From Neutral by Cantor Fitzgerald

Dow Jones
·
15 Apr

Verve Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
15 Apr

Cantor Fitzgerald Upgrades Verve Therapeutics to Overweight From Neutral

MT Newswires Live
·
15 Apr

Clover Health Investments Leads The Charge In These 3 Promising Penny Stocks

Simply Wall St.
·
15 Apr

Guggenheim Reaffirms Their Buy Rating on Verve Therapeutics (VERV)

TIPRANKS
·
15 Apr

Canaccord Genuity Reaffirms Their Buy Rating on Verve Therapeutics (VERV)

TIPRANKS
·
15 Apr

Cantor upgrades Verve Therapeutics to Overweight after positive data

TIPRANKS
·
15 Apr

Verve Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald

TIPRANKS
·
15 Apr

U.S. RESEARCH ROUNDUP- CNB Financial, Disney, Triumph Group

Reuters
·
15 Apr

Verve Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
15 Apr

This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life. -- Barrons.com

Dow Jones
·
15 Apr

Verve Therapeutics price target raised to $25 from $15 at H.C. Wainwright

TIPRANKS
·
15 Apr

Verve Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $25 From $15

THOMSON REUTERS
·
15 Apr

Verve Shares Soar 21% After New Gene-Editing Trial Shows No Safety Concerns

Bloomberg
·
14 Apr

Top Premarket Gainers

MT Newswires Live
·
14 Apr

Verve Therapeutics Shares up 22.7% at $4 Premarket After Initial Early-Stage Data for Gene Editing Therapy

THOMSON REUTERS
·
14 Apr

Verve Therapeutics' VERVE-102 Gene Editing Therapy Trial Shows Positive Initial Data in Clinical Trial

MT Newswires Live
·
14 Apr